Sigman (ASX:SIG) - CEO and Managing Director, Vikesh Ramsunder
CEO and Managing Director, Vikesh Ramsunder
Incoming Managing Director and CEO, Vikesh Ramsunder Source: Clicks Group Facebook
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Sigma Healthcare (SIG) appoints a new Managing Director and CEO to lead the company
  • Current Group CEO of the Clicks Group in South Africa, Vikesh Ramsunder, will take the helm of the company, with a $1 million per annum remuneration
  • The appointment follows an extensive search process after Sigma’s current CEO, Mark Hooper, announced he would step down at the end of October
  • Mr Ramsunder will commence his role with Sigma in February 2022 following the completion of his notice period
  • Sigma Healthcare is trading 1.64 per cent lower at 60 cents at 11:37 am AEST

Sigma Healthcare (SIG) has appointed a new Managing Director and CEO to lead the company.

Current Group CEO of the Clicks Group in South Africa, Vikesh Ramsunder, will take the helm of the company. The appointment comes with a $1 million per annum remuneration and sign on rights of $1,400,000, vested in two equal tranches. Short and long term incentives will also be offered, if performance targets are met.

Sigma Chairman Ray Gunston said the board was delighted to announce that someone of Mr Ramsunder’s calibre would be leading the company into the future.

“He was a compelling candidate who comes with extensive experience in wholesaling, logistics, pharmacy and retail,” Mr Gunston said.

“He has been integral to the growth of the Clicks Group, which is now one of the largest wholesale, pharmacy and retail operations in Africa, with a market capitalisation around $6 billion, the equivalent of an ASX100 company in Australia.”

The appointment follows an extensive search process after Sigma’s current CEO, Mark Hooper, announced he would be stepping down. Mark Hooper will remain with Sigma until the end of October.

In recognition for him now agreeing to remain with Sigma until the end of January 2022, Sigma has agreed to increase Mr Hooper’s monthly total fixed remuneration for the three-month period by 50 per cent.

Sigma Healthcare was trading 1.64 per cent lower at 60 cents at 11:37 am AEST.

SIG by the numbers
More From The Market Online

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…

Genetic Signatures wins TGA greenlight for flu test device – just before winter

Genetic Signatures (ASX:GSS) shares were down -1.45% to 68cps on Monday, even as the company reported…

PYC Therapeutics takes Polycystic Kidney Disease drug to human trials

PYC Therapeutics takes its latest drug for Polycystic Kidney Disease, characterized by the formation of cysts…